Amit Sehrawat

Medical Oncologist, Explorer/अन्वेषक & Solivagant RT's are not endorsements

[Amit Sehrawat @dramitsehrawat]

Clinicopathologic Profile and Treatment Outcomes of Colorectal Cancer in Young Adults: A Multicenter Study From India | JCO Global Oncology https://t.co/kLE00EkxN4
@BIRAC_2012 #NOCI
@aiimsrishi @mridulkhanna

[Luis A. Morgado-MD @DrCriticalCare]

7 Pecados Médicos

(Publicados por Richard Asher en 1949)
Siguen vigentes :

1.- Obscuridad: (Utilizar lenguaje complicado y rebuscado)
Si no eres capaz de explicarlo de manera simple, quizá tú tampoco lo entiendas.
2.- Crueldad: (Realizar Procedimientos innecesarios)
3.- Malas Maneras (Falta de cortesía básica)
4.- Sobreespecializacion (centrarse en un solo órgano olvidando todo el paciente
5.- Amor por lo Raro (obsesionarse con casos raros)
6.- Estupides común (pensar en protocolos, algoritmos etc) no tener criterio propio ni juicio clínico
7.- Pereza (no esforzarse, no revisar, no profundizar)

[Amit Sehrawat @dramitsehrawat]

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting | JCO Global Oncology https://t.co/FGj2m4RBNT

[Erman Akkus @Erman_Akkus]

💉IO and major ADCs premedications

#cancer #oncology #MedX @OncoAlert

[Vivek Subbiah, MD @VivekSubbiah]

Liquid Biopsies for Cancer: A Translational Science Review | Oncology | JAMA | JAMA Network https://t.co/ldxE5WhLQS

[Nature Cancer @NatureCancer]

💫Online today
The Review on intratumor heterogeneity by @Jonathancmwan, @NickyMcGranahan and @CharlesSwanton

🔗https://t.co/i5ryGR2lej

Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: https://t.co/kJQO5ZYuOC

[Amit Sehrawat @dramitsehrawat]

GEMOX demonstrated efficacy comparable to GEM-CIS despite poorer performance status, with better tolerability, lower hematologic. Its biweekly schedule and logistical advantages https://t.co/EpLHoJuodE

[Amit Sehrawat @dramitsehrawat]

Translation of the strength, assistance in walking, rising from a chair, climbing stairs, and falls questionnaire into Hindi https://t.co/gcRJmkKN1w

[Amit Sehrawat @dramitsehrawat]

Presented at #ESMOGI2026

[Amit Sehrawat @dramitsehrawat]

Real World First Line Treatment Patterns and Outcomes in Advanced Metastatic Gall Bladder Cancer from AIIMS Rishikesh
Interesting data at the time of Global Cisplatin Shortage.
#RWE #CisplatinShortage #GBC

[Felipe Templo Jr. ,MD, MBA 🕊 @thejourneymate]

Immunohistochemistry 101 🔬

(c): Sumit Kumar

[Dr. Arkadip MD @pathognosis22]

PDL1 IHC scoring guideline
#PD1 #PDL1 #CTLA4 #HN #GEJ #NSCLC #TNBC #ASCO #IASLC #NCCN #FDA #WHO #NEET #NEETSS

[Toni Choueiri, MD @DrChoueiri]

In 1948, Sidney Farber and colleagues published his work in @NEJM that helped open the door to modern chemotherapy.

Seeing that history from the same institution — especially after a remarkable #ASCO26 with major plenary contributions and @NEJM papers from @DanaFarber — is humbling.

A powerful reminder that progress in oncology is built across generations: by patients, scientists, clinicians, and teams who keep asking what might be possible.

[Amit Sehrawat @dramitsehrawat]

Tolerance of gemcitabine–oxaliplatin (GEMOX) in advanced and metastatic gallbladder cancer: A real-world, single-center retrospective study from north India. | Journal of Clinical Oncology https://t.co/JfEchhn5Sh @aiimsrishi @ASCO @JCO_ASCO #ASCO2026 #RWE

[Amit Sehrawat @dramitsehrawat]

Primary Platinum-Resistant Ovarian Cancer: Clinicopathologic Correlates and Outcomes From a Multicenter Prospective Indian Registry | JCO Global Oncology https://t.co/fYa2gQDS8S @aiimsrishi @OfficialJipmer @SunuCyriac @BIRAC_2012 @JCOGO_ASCO

[Amit Sehrawat @dramitsehrawat]

The Evidence-based Guidelines for Lung Cancer Management published by the MoHFW/DHR-DGHS provide recommendations based on careful consideration of available evidence. @DeptHealthRes @aiimsrishi https://t.co/VvJtvVX96x

[Amit Sehrawat @dramitsehrawat]

@aiimsrishi @ejsotweets

[Amit Sehrawat @dramitsehrawat]

Study of TPX NACT in borderline-inoperable LAOSCC (n=45) showed a 53.3% response rate. 28.9% converted to operability, all achieving R0 resection.TPX is a pragmatic option to enable surgery in this oncological "grey zone."https://t.co/3dMCXbmM83

[AIIMS RISHIKESH @aiimsrishi]

@aiimsrishi in newspaper
@MoHFW_INDIA
@JPNadda
@meenusingh4

[Dr. AK 🇮🇳 @docakx]

Few tumours produce prostraglandins and cause diarrhea. A NSAID like indomethacin can help.

-Medullary thyroid carcinoma (MTC)
-Large villous adenomas (especially rectum or distal colon)
-Gastroenteropancreatic neuroendocrine tumours (GEP-NETs / carcinoid tumours)
-VIPomas (rarely co-secrete prostaglandins)

[Dr. Foxpaws Fauxpas @foxpaws_onco]

Grades of #chemotherapy response across tumors

Higher is better in - Osteosarcoma Huvos, Ovarian CRS, Miller Payne Breast, Dvorak Rectum

Lower is better in - Ryan CAP/Mandard/Becker GI malignancies, #RCB in breast
#onctwitter #oncology #cancer #medtwitter #pathology